SciRhom is a biotechnology company developing therapies for autoimmune diseases, focusing on humanized antibodies against iRhom2 to control inflammation.

SciRhom

SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Founded in late 2016, we develop first-in-class antibodies against iRhom2, a key modulator of several crucial pro-inflammatory signalling pathways, including TNF-alpha signalling.  Following the preclinical and early clinical development of these monoclonal antibodies, we are aiming to provide superior treatment options to currently existing inhibitors of TNF-alpha signaling. SciRhom is poised to transform the lives of patients with autoimmune diseases.

High-Tech Grunderfonds

Hospital for Special Surgery

📢 One big step closer to evaluating our first #iRhom2-targeting therapeutic antibody in human studies. ⬇
 
The approval of a clinical trial application by the Austrian regulatory authorities (BASG/AGES) for our development program SR-878 paves the way for the upcoming clinical study in the second half of 2024. 
 
SR-878 targets iRhom2, a crucial regulator of TACE/ADAM-17, which is a master switch for various disease-relevant signaling pathways. In the upcoming study, we aim to evaluate safety in healthy volunteers and provide initial evidence of clinical activity in a second part of the study.
 
Stay tuned for more on SciRhom’s unique approach for breaking through the therapeutic ceiling in autoimmune diseases.
 
#iRhom #iRhom2 #TACE #ADAM17 #IBD #arthritis #clinicalresearch #autoimmune

SciRhom Files Clinical Trial Application for First-in-Human Trials of Novel Antibody Against Autoimmune Diseases. A special thank you goes to our team and partner WuXi Biologics and other vendors for their exceptional work and collaboration.

Find more information on https://scirhom.com

#innovation #clinicaltrial #scirhom #arthritis #ibd #biologics #biotech

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Jul 12, 2024 1:37 AM	6ed4d1d3
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Jul 12, 2024 6:53 PM	d30bfc86
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Jul 12, 2024 1:37 AM	1db3bdfa
translate crunchbase fundingrounds	general
peers	general	Jul 12, 2024 1:37 AM	c7b66e96
news basic	general	Jul 12, 2024 1:37 AM	647f736f
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:SCIRHOM

SciRhom